LEXINGTON, Mass., July 23, 2015 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) has been granted two patents from the U.S. Patent and Trademark Office (U.S. Patent # 8,992,983 and U.S. patent # 9,061,352), which cover the composition of matter for the Company's underlying iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted) inhaled dry powder technology as well as methods for treating a subject using respirable dry powders. The proprietary combination of salts and amino acids has been engineered to create small and dense particles possessing properties that have the potential to enable or improve new approaches for the treatment of lung disease or facilitate greater efficiency in the delivery of pharmaceuticals to the lungs. The Company now was 36 issued patents worldwide covering the iSPERSE™ technology through at least 2030.
"These issuances build upon previously issued international patents and reflect our aggressive strategy to broadly protect the global IP position of our core iSPERSE™ technology," said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. "Our issued and pending patents are the result of the research and development conducted in our labs and which formed the basis for our most advanced clinical-stage candidate, a branded generic bronchodilator for COPD, and our proprietary development candidate, an anti-fungal for cystic fibrosis. We look forward to the receipt of additional patents covering distinct as well as overlapping components and combinations of our iSPERSE™ technology and drug development candidates."
Pulmatrix's iSPERSE™ technology has the potential to solve significant limitations of other inhaled technologies available today, such as nebulizers, metered dose inhalers, and conventional lactose blend dry powder inhalers. iSPERSE™ particles are engineered to be small, dense, and easily dispersible upon inhalation, thereby delivering the drugs more efficiently to the airways. This targeted airway delivery of drugs also reduces systemic exposure and potential side effects. Importantly, unlike other traditional inhalation technologies, iSPERSE™ is also flow rate independent, which should provide reliable dose delivery across patient populations regardless of the status of patient lung function.
"These patent grants further validate the novelty and relevance of the iSPERSE™ technology," said David Hava, Ph.D., chief scientific officer for Pulmatrix. "Specifically, they recognize the uniqueness of our ability to produce aerodynamically small, dense powders that maintain remarkable dispersibility profiles across a range of drug classes and underscore the differentiation of our technology from conventional and earlier particle engineering approaches."
About Pulmatrix Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaboration with partners. This includes PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) in collaboration with Mylan N.V., and other potential first-in-class treatments. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
FORWARD-LOOKING STATEMENTS Certain statements in this letter that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that," "looks forward," "may," "plans," "seeks," "projects," "targets," and "would" or the negative of such terms or other variations on such terms or comparable terminology. Pulmatrix cautions that such statements involve risks and uncertainties that may materially affect Pulmatrix's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to enforce issued patents and prosecute new patents in order to maintain a proprietary position or freedom to operate, the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital; and the ability to secure and enforce legal rights related to the Pulmatrix's products. A discussion of these and other factors, including risks and uncertainties with respect to Pulmatrix, is set forth in the registration statement on Form S-4 filed by Pulmatrix on April 15, 2015, as amended. Pulmatrix disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Pulmatrix, Inc.